Pain News and Research

Latest Pain News and Research

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Heart Rhythm Society, ECAS and EHRA develop 2012 expert consensus statement on AF ablation

The 2012 expert consensus statement on catheter and surgical ablation of atrial fibrillation was developed by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the European Cardiac Arrhythmia Society (ECAS) and published in their respective journals: Heart Rhythm, EP Europace and the Journal of Interventional Cardiovascular Electrophysiology (JICE).

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

FAST-MI highlights young women at risk for heart disease

An analysis of four French registries has shown a dramatic drop in ST-segment-elevation myocardial infarction mortality from 1995 to 2010, accompanied by a significant change in patient characteristics.

29 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Johns Hopkins' Armstrong Institute for Patient Safety and Quality has received an $8.9 million grant from the Gordon and Betty Moore Foundation, the first award given as part of an ambitious new $500 million, 10-year program designed to eliminate all preventable harms that patients experience in the hospital.

29 Aug 2012

New treatment for severe dry eye is now available at U-M’s Kellogg

A new treatment available at the University of Michigan Kellogg Eye Center—prosthetic replacement of the ocular surface ecosystem or PROSE—provides relief to patients who suffer from severe dry eye, often the result of cancer or complex corneal disease.

29 Aug 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

Ultra-fast 320-detector CT scanner can accurately diagnose arterial blockages

An ultra-fast, 320-detector computed tomography (CT) scanner can accurately sort out which people with chest pain need - or don't need - an invasive procedure such as cardiac angioplasty or bypass surgery to restore blood flow to the heart, according to an international study. Results of the study, which involved 381 patients at 16 hospitals in eight countries, are scheduled to be presented at the European Society of Cardiology Congress in Munich, Germany, on August 28.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

St. Jude Medical, Inc., a global medical device company, today announced that interim data demonstrated the company's EnligHTN renal denervation system is safe and effective for the treatment of resistant hypertension.

29 Aug 2012

Study looks at exercise habits among cancer patients

Numerous studies have shown the powerful effect that exercise can have on cancer care and recovery. For patients who have gone through breast or colon cancer treatment, regular exercise has been found to reduce recurrence of the disease by up to 50 percent.

29 Aug 2012

One in four women experience vulvar pain at some point in their lifetime

According to a study conducted by the University of Michigan, one in four women experience vulvar pain at some point in their lifetime. Like all medical concerns, vulvar pain causes both physical and mental stress. Additionally, vulvar pain can have an adverse effect on intimacy and relationships.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Major decline in early mortality for STEMI patients: French registries

Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.

28 Aug 2012

Views on Medicare: Rep. Kathy Hochul's campaign; Ryan's vision; Wyden's role

Kathy Hochul is a young, first-term Democratic congresswoman fighting for her political life in a solidly Republican district outside Buffalo, N.Y. Unlike most of that liberal state, this is Romney country; a poll last week showed the GOP candidate ahead of President Obama in her district by a whopping 12 points.

28 Aug 2012

Community-based pharmacists could provide added resource in identifying knee OA

Canadian researchers have determined that community-based pharmacists could provide an added resource in identifying knee osteoarthritis (OA). The study, published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), represents the first evidence supporting a collaborative approach to managing knee OA.

28 Aug 2012

Pain News and Research

Latest Pain News and Research

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Heart Rhythm Society, ECAS and EHRA develop 2012 expert consensus statement on AF ablation

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

FAST-MI highlights young women at risk for heart disease

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

New treatment for severe dry eye is now available at U-M’s Kellogg

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Ultra-fast 320-detector CT scanner can accurately diagnose arterial blockages

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

Study looks at exercise habits among cancer patients

One in four women experience vulvar pain at some point in their lifetime

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Major decline in early mortality for STEMI patients: French registries

Views on Medicare: Rep. Kathy Hochul's campaign; Ryan's vision; Wyden's role

Community-based pharmacists could provide added resource in identifying knee OA

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Pain News and Research

Latest Pain News and Research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Newsletters you may be interested in